| Submission declined on 10 October 2024 by Significa liberdade (talk). This submission appears to be taken from https://biopic.pku.edu.cn/en/researchteam/528447.htm. Wikipedia cannot accept material copied from elsewhere, unless it explicitly and verifiably has been released to the world under a suitably free and compatible copyright license or into the public domain and is written in an acceptable tone—this includes material that you own the copyright to. You should attribute the content of a draft to outside sources, using citations, but copying and pasting or closely paraphrasing sources is not acceptable. The entire draft should be written using your own words and structure.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
|  |
This submission has now been cleaned of the above-noted copyright violation and its history redacted by an administrator to remove the infringement. If re-submitted (and subsequent additions do not reintroduce copyright problems), the content may be assessed on other grounds.| Submission declined on 12 August 2024 by LR.127 (talk). This submission's references do not show that the subject qualifies for a Wikipedia article—that is, they do not show significant coverage (not just passing mentions) about the subject in published, reliable, secondary sources that are independent of the subject (see the guidelines on the notability of people). Before any resubmission, additional references meeting these criteria should be added (see technical help and learn about mistakes to avoid when addressing this issue). If no additional references exist, the subject is not suitable for Wikipedia. Declined by LR.127 2 months ago. | |
Comment: The sources given are primary sources (works made by the subject), and don't establish notability on Wikipedia. If you are connected to the subject, please thoroughly read WP:COI. LR.127 (talk) 22:52, 12 August 2024 (UTC)
Yunlong Richard Cao | |
|---|---|
曹云龙 | |
| Alma mater | Harvard University |
| Known for | SARS-CoV-2 evolution |
| Awards | Nature's 10 (2022) |
| Scientific career | |
| Fields | Immunology |
| Institutions | Biomedical Pioneering Innovation Center, Peking University |
Yunlong Richard Cao Chinese:曹云龙; pinyin: Cáo Yúnlóng) is a Chinese immunologist and assistant professor at Peking University's Biomedical Pioneering Innovation Center (BIOPIC).[1][2] Known for his work on SARS-CoV-2 evolution and antibody responses, Cao has made significant contributions to understanding humoral immunity and developing antibody therapeutics.[3][4]His research focuses on B-cell mediated adaptive immune response, antibody drugs, and vaccine design.[5] Cao gained international recognition for his ability to predict SARS-CoV-2 mutations and was named one of Nature's "Ten People Who Mattered" in 2022 for his role in tracking the evolution of the virus.[6] He was also listed as one of the "Innovators under 35" by the MIT Technology Review in 2021.[7]
Education and career
editCao completed his undergraduate studies in Physics at Zhejiang University, graduating in 2014. He then went on to earn a Ph.D. in Chemistry from Harvard University in 2019 while under the research direction of Prof. Xiaoliang Sunney Xie.[1] Following his Ph.D, he came back to China and became a Research Associate at Biomedical Pioneering Innovation Center (BIOPIC), Peking University. In 2023, Cao started an independent laboratory as assistant professor.[1][2][8]
Academic honors and service
edit- 2024 Xplorer Prize[9]
- 2023 The Coalition for Epidemic Preparedness Innovations (CEPI) Scientific Advisory Committee[10]
- 2022 Beijing Outstanding Young Talent Award (ZhongGuanCun Award)[11]
- 2022 China's top 10 scientific advances[12]
- 2022 China's top 10 advances in life sciences[13]
- 2022 Nature's 10 ("Ten people who helped shape science in 2022")[6][14]
- 2021 "35 Innovators Under 35" (China) by MIT Technology Review[7]
Selected publications
edit- Yisimayi A, Song W, Wang J, Jian F, Yu Y, Chen X, Xu Y, Yang S, Niu X, Xiao T, Wang J, Zhao L, Sun H, An R, Zhang N, Wang Y, Wang P, Yu L, Lv Z, Gu Q, Shao F, Jin R, Shen Z, Xie XS, Wang Y, Cao Y (January 2024). "Repeated Omicron exposures override ancestral SARS-CoV-2 immune imprinting". Nature. 625 (7993): 148–156. Bibcode:2024Natur.625..148Y. doi:10.1038/s41586-023-06753-7. PMC 10764275. PMID 37993710.
- Cao Y, Jian F, Wang J, Yu Y, Song W, Yisimayi A, Wang J, An R, Chen X, Zhang N, Wang Y, Wang P, Zhao L, Sun H, Yu L, Yang S, Niu X, Xiao T, Gu Q, Shao F, Hao X, Xu Y, Jin R, Shen Z, Wang Y, Xie XS (February 2023). "Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution". Nature. 614 (7948): 521–529. Bibcode:2023Natur.614..521C. doi:10.1038/s41586-022-05644-7. PMC 9931576. PMID 36535326.
- Cao Y, Yisimayi A, Jian F, Song W, Xiao T, Wang L, Du S, Wang J, Li Q, Chen X, Yu Y, Wang P, Zhang Z, Liu P, An R, Hao X, Wang Y, Wang J, Feng R, Sun H, Zhao L, Zhang W, Zhao D, Zheng J, Yu L, Li C, Zhang N, Wang R, Niu X, Yang S, Song X, Chai Y, Hu Y, Shi Y, Zheng L, Li Z, Gu Q, Shao F, Huang W, Jin R, Shen Z, Wang Y, Wang X, Xiao J, Xie XS (August 2022). "BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection". Nature. 608 (7923): 593–602. Bibcode:2022Natur.608..593C. doi:10.1038/s41586-022-04980-y. PMC 9385493. PMID 35714668.
- Cao Y, Wang J, Jian F, Xiao T, Song W, Yisimayi A, Huang W, Li Q, Wang P, An R, Wang J, Wang Y, Niu X, Yang S, Liang H, Sun H, Li T, Yu Y, Cui Q, Liu S, Yang X, Du S, Zhang Z, Hao X, Shao F, Jin R, Wang X, Xiao J, Wang Y, Xie XS (February 2022). "Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies". Nature. 602 (7898): 657–663. Bibcode:2022Natur.602..657C. doi:10.1038/s41586-021-04385-3. PMC 8866119. PMID 35016194.
- Cao Y, Su B, Guo X, Sun W, Deng Y, Bao L, Zhu Q, Zhang X, Zheng Y, Geng C, Chai X, He R, Li X, Lv Q, Zhu H, Deng W, Xu Y, Wang Y, Qiao L, Tan Y, Song L, Wang G, Du X, Gao N, Liu J, Xiao J, Su XD, Du Z, Feng Y, Qin C, Qin C, Jin R, Xie XS (July 2020). "Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients' B Cells". Cell. 182 (1): 73–84.e16. doi:10.1016/j.cell.2020.05.025. PMC 7231725. PMID 32425270. 1229
- Yue C, Song W, Wang L, Jian F, Chen X, Gao F, Shen Z, Wang Y, Wang X, Cao Y (March 2023). "ACE2 binding and antibody evasion in enhanced transmissibility of XBB.1.5". The Lancet. Infectious Diseases. 23 (3): 278–280. doi:10.1016/S1473-3099(23)00010-5. PMC 9897732. PMID 36746173.
- Cao Y, Song W, Wang L, Liu P, Yue C, Jian F, Yu Y, Yisimayi A, Wang P, Wang Y, Zhu Q, Deng J, Fu W, Yu L, Zhang N, Wang J, Xiao T, An R, Wang J, Liu L, Yang S, Niu X, Gu Q, Shao F, Hao X, Meng B, Gupta RK, Jin R, Wang Y, Xie XS, Wang X (November 2022). "Characterization of the enhanced infectivity and antibody evasion of Omicron BA.2.75". Cell Host & Microbe. 30 (11): 1527–1539.e5. doi:10.1016/j.chom.2022.09.018. PMC 9531665. PMID 36270286.
- Yang S, Yu Y, Xu Y, Jian F, Song W, Yisimayi A, Wang P, Wang J, Liu J, Yu L, Niu X, Wang J, Wang Y, Shao F, Jin R, Wang Y, Cao Y (February 2024). "Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressure". The Lancet. Infectious Diseases. 24 (2): e70–e72. doi:10.1016/S1473-3099(23)00744-2. PMID 38109919.
- Cao Y, Jian F, Zhang Z, Yisimayi A, Hao X, Bao L, Yuan F, Yu Y, Du S, Wang J, Xiao T, Song W, Zhang Y, Liu P, An R, Wang P, Wang Y, Yang S, Niu X, Zhang Y, Gu Q, Shao F, Hu Y, Yin W, Zheng A, Wang Y, Qin C, Jin R, Xiao J, Xie XS (December 2022). "Rational identification of potent and broad sarbecovirus-neutralizing antibody cocktails from SARS convalescents". Cell Reports. 41 (12): 111845. doi:10.1016/j.celrep.2022.111845. PMC 9712074. PMID 36493787.
- Cao Y, Yisimayi A, Jian F, Song W, Xiao T, Wang L, Du S, Wang J, Li Q, Chen X, Yu Y, Wang P, Zhang Z, Liu P, An R, Hao X, Wang Y, Wang J, Feng R, Sun H, Zhao L, Zhang W, Zhao D, Zheng J, Yu L, Li C, Zhang N, Wang R, Niu X, Yang S, Song X, Chai Y, Hu Y, Shi Y, Zheng L, Li Z, Gu Q, Shao F, Huang W, Jin R, Shen Z, Wang Y, Wang X, Xiao J, Xie XS (August 2022). "BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection". Nature. 608 (7923): 593–602. doi:10.1038/s41586-022-04980-y. PMC 9385493. PMID 35714668.
- Cui Z, Liu P, Wang N, Wang L, Fan K, Zhu Q, Wang K, Chen R, Feng R, Jia Z, Yang M, Xu G, Zhu B, Fu W, Chu T, Feng L, Wang Y, Pei X, Yang P, Xie XS, Cao L, Cao Y, Wang X (March 2022). "Structural and functional characterizations of infectivity and immune evasion of SARS-CoV-2 Omicron". Cell. 185 (5): 860–871.e13. doi:10.1016/j.cell.2022.01.019. PMC 8786603. PMID 35120603.
- Qu L, Yi Z, Shen Y, Lin L, Chen F, Xu Y, Wu Z, Tang H, Zhang X, Tian F, Wang C, Xiao X, Dong X, Guo L, Lu S, Yang C, Tang C, Yang Y, Yu W, Wang J, Zhou Y, Huang Q, Yisimayi A, Liu S, Huang W, Cao Y, Wang Y, Zhou Z, Peng X, Wang J, Xie XS, Wei W (May 2022). "Circular RNA vaccines against SARS-CoV-2 and emerging variants". Cell. 185 (10): 1728–1744.e16. doi:10.1016/j.cell.2022.03.044. PMC 8971115. PMID 35460644.
External links
editReferences
edit- ^ a b c "Yunlong Cao, PhD". BIOPIC, PKU. Retrieved 10 August 2024.
- ^ a b "Yunlong Cao, PhD". Peking-Tsinghua Center for Life Sciences. Retrieved 10 August 2024.
- ^ "Cao Lab". Biomedical Pioneering Innovation Center (BIOPIC). Beijing, China: Peking University.
- ^ "Yunlong Cao_Nature's 10". Pandaily. Retrieved 29 October 2024.
- ^ Liu C. Wellington D (ed.). "Assistant Professor Yunlong Cao visits CAMS Oxford Institute". CAMS Oxford Institute, Nuffield Department of Medicine. University of Oxford.
- ^ a b "2022 Nature's 10". Nature. Springer Nature Limited. Retrieved 10 August 2024.
- ^ a b "MIT Innovators under 35: Yunlong Richard Cao". MIT Technology Review. Massachusetts Institute of Technology. 2021. Retrieved 10 August 2024.
Contributing to the development of SARS-COV-2 vaccines and therapeutics.
- ^ "Yunlong Cao". Changping Laboratory. Retrieved 10 August 2024.
- ^ "2024 Xploer Prize Awardees". XPLORER PRIZE.
- ^ "SAC Members". CEPI Scientific Advisory Committee. The Coalition for Epidemic Preparedness Innovations (CEPI). Retrieved 10 August 2024.
- ^ "北京市科技进步奖" [Beijing Science and Technology Progress Award] (PDF). 2022 年北京市科学技术奖授奖清单 (List of Beijing Science and Technology Awards) (in Chinese). Retrieved 10 August 2024.
- ^ "China's Top 10 Science Advances in 2022". Bulletin of the Chinese Academy of Sciences. Retrieved 10 August 2024.
- ^ "Research by CPL Leading Scientists among China's top 10 advances in life sciences in 2022". Changping Laboratory. Retrieved 10 August 2024.
- ^ Cite error: The named reference
央广网was invoked but never defined (see the help page).